Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Industry News - Diagnostics
Trial Results Support Use of CEA-Scan in Cancer Patients
September 11th, 1995
Immunomedics Inc., Morris Plains, New Jersey, announced that results of a multicenter Phase I/II trial suggest the safety and diagnostic utility of the company's imaging agent, CEA-Scan, for the detection of cancerous lesions in patients with primary breast cancer. The study's aim was to assess the performance of CEA-Scan as part of the initial clinical workup of breast cancer patients. The trial's results were presented at the annual meeting of the European Association of Nuclear Medicine, held in Brussels, Belgium. In 49 women with operable, primary breast cancer, CEA-Scan showed excellent sensitivity, specificity and accuracy compared to...
Source: Women's Health Weekly (1995-09-11)
|
